Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01233921 | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | completed | N/A | 6 | Martin, PaulOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 133 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 31, 2014 | clinicaltrials |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| completed |
| Phase 1 |
| 42 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Mar 17, 2014 |
| clinicaltrials |
| NCT00086580 | Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients | completed | Phase 3 | 335 | Genzyme, a Sanofi CompanyINDUSTRY | 15 | Mar 13, 2014 | clinicaltrials |
| NCT00328198 | Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 86 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Mar 13, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00919321 | The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL(KLL2) | completed | Phase 4 | 32 | Tampere University HospitalOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01841489 | A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics | completed | Phase 1 | 56 | Gilead SciencesINDUSTRY | 1 | Feb 7, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT00458679 | Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells(PRIMAL) | completed | Phase 1 | 6 | Baylor College of MedicineOTHER | 1 | Feb 3, 2014 | clinicaltrials |
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | terminated | Phase 2 | 16 | Marshall UniversityOTHER | 1 | Dec 12, 2013 | clinicaltrials |
| NCT00836043 | Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | terminated | — | 6 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Dec 3, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00006226 | Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01185262 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia(LLC-LENAR-08) | completed | Phase 1 | 25 | MD Anderson International Spain SAOTHER | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 70 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00026182 | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01109264 | Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia | completed | Phase 2 | 147 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 23, 2013 | clinicaltrials |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | completed | Phase 1 | 113 | Tesaro, Inc.INDUSTRY | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00089154 | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2013 | clinicaltrials |
| NCT00514696 | Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia(PR-CS008) | completed | Phase 2 | 12 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 17, 2013 | clinicaltrials |
| NCT00868413 | Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 | 32 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Jun 7, 2013 | clinicaltrials |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00017472 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00098488 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00873457 | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 16 | Daphne FriedmanOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00593944 | Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)(MDX1342-02) | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00849654 | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma(PCYC-04753) | completed | Phase 1 | 66 | Pharmacyclics LLC.INDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00001586 | Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | May 15, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2014source: clinicaltrials